Last updated 2026-07-30
TL;DR
There is no agreed-upon 'success rate' for methylene blue because it depends entirely on what you're treating. For FDA-approved methemoglobinemia, it works reliably and fast in most patients [1]. For nootropic, mitochondrial, or anti-aging use, human data is thin: a few small trials show modest memory or mood effects, but nothing supports a population-wide success rate.
what does 'success rate' even mean for methylene blue?
The honest answer is that this question assumes methylene blue is one thing with one job. It isn't. The FDA-approved use is treating methemoglobinemia, a blood disorder where hemoglobin can't release oxygen properly [1]. Everything else, focus, mitochondrial support, longevity, mood, is off-label, meaning doctors can legally prescribe it that way but the drug wasn't studied or approved for those purposes. So "success rate" splits into at least three separate questions: does it work for methemoglobinemia (yes, well-documented), does it work for cognitive or mood complaints (some small human trials, mixed results), and does it slow aging or boost mitochondria (rodent and cell data only, no human success rate exists because no one has run the trial). Conflating these is where most of the internet gets this topic wrong. This article treats them separately, with the actual numbers from actual studies, not vibes from forum threads.
how effective is methylene blue for methemoglobinemia, its actual approved use?
This is the one place a real success rate exists. Methylene blue has been used to treat acquired methemoglobinemia since the 1930s, and it remains first-line therapy today [1]. The FDA label for methylene blue injection (marketed as Provayblue) states it is indicated for the treatment of drug- or chemical-induced methemoglobinemia [1]. Clinical response is typically fast. Methemoglobin levels usually start dropping within an hour of an IV dose, and the standard dose is 1 to 2 mg/kg given intravenously over several minutes, which can be repeated if methemoglobin remains elevated after 30 to 60 minutes [1]. Case series and pharmacology reviews describe most patients responding to one or two doses, though exact aggregate success percentages vary by cause and severity of the methemoglobinemia and there isn't one clean randomized trial number to quote. The important caveat: this success rate applies to pharmaceutical-grade methylene blue given by a clinician who is watching methemoglobin levels and ruling out G6PD deficiency first, not to a bottle of supplement-shop methylene blue taken at home.
does methylene blue actually improve focus or cognition in humans?
The human data here is real but small, and "success rate" is the wrong frame for it. The most cited study is a 2016 University of Texas Southwestern trial by Rodriguez et al., published in Radiology, which gave healthy adults a single low dose (about 0.5 mg/kg) of methylene blue and used fMRI plus memory tasks [2]. It found improved short-term memory retention and increased activity in brain regions tied to attention and memory, in a small sample of adults. That's one dose, one small trial, one outcome measure. It is not a population success rate, and it hasn't been replicated at scale. Earlier work by the same research group, including a 2011 study in Radiology, reported similar low-dose effects on working memory and mood in healthy volunteers [3]. What's missing: no large randomized controlled trial has tested methylene blue against placebo for everyday focus, ADHD-type attention, or long-term nootropic use in healthy people. Anyone quoting a specific percentage improvement in focus for general use is extrapolating past what these small trials measured. For a fuller breakdown of what these before/after style studies actually showed, see methylene blue before and after and the methylene blue results timeline.
what does the research say about methylene blue and memory or dementia?
The strongest human signal for a cognition-adjacent use comes from Alzheimer's research, and even there the results are contested. Methylene blue's reduced form (leucomethylene blue) is the active ingredient in a drug candidate called LMTM (also known as TRx0237 or hydromethylthionine), studied specifically as a tau aggregation inhibitor. A large Phase 3 trial published in The Lancet Neurology in 2021 (the TRx-237-005 study) tested LMTM in patients with mild Alzheimer's disease and found it did not meet its primary cognitive endpoints compared to a low-dose comparator arm [4]. Earlier Phase 2/3 trials had produced mixed, debated results, with some post hoc analyses suggesting benefit in patients on LMTM monotherapy, but the definitive trials did not confirm a clear disease-modifying effect [4]. The upshot: for dementia specifically, the closest thing to a real success rate is "failed to beat its comparator in the definitive trial." That's a meaningfully different story than what marketing copy sometimes implies, and it should temper expectations for methylene blue as a long-term brain-protective agent.
is there any human evidence for methylene blue and mitochondrial or antiaging effects?
Almost none, and what exists is preclinical. Methylene blue can act as an alternative electron carrier in the mitochondrial electron transport chain, a mechanism demonstrated in isolated mitochondria and cell culture studies going back decades [5]. Rodent studies, including work published in journals like Neurobiology of Aging, have shown low-dose methylene blue improving markers of oxidative stress and, in some memory-impaired rat models, improving learning task performance [6]. None of that is a human success rate. Nobody has published a randomized human trial measuring mitochondrial function, biological age markers, or lifespan-relevant endpoints in people taking methylene blue for longevity. The mitochondrial and anti-aging claims you see marketed are extrapolations from cell and animal data, not a demonstrated human outcome, and treating a rat finding as a human result is exactly the kind of overreach this space is full of. If you're weighing whether the current evidence justifies trying it, is methylene blue worth it and methylene blue pros and cons go through the tradeoffs in more depth.
does methylene blue help with depression or mood?
There's a real pharmacological reason to ask this question: methylene blue inhibits monoamine oxidase A (MAO-A) at the doses used clinically, which is the same mechanism as older MAOI antidepressants [7]. A handful of small trials, including work from the 1980s using low-dose methylene blue as an add-on treatment for bipolar depression, reported mood improvement compared to placebo [8]. These trials are old, small, and haven't been repeated with modern trial standards. There's no current, well-powered study establishing a success rate for methylene blue as a standalone antidepressant, and no regulatory body has approved it for depression. The bigger issue is safety, more than efficacy. Because methylene blue is an MAOI, combining it with SSRIs, SNRIs, or other serotonergic drugs (including some over-the-counter cough medicines and supplements like St. John's Wort) can trigger serotonin syndrome, a potentially life-threatening reaction. The FDA has issued a specific drug safety communication warning about this interaction [7]. Anyone on a serotonergic antidepressant should not use methylene blue without their prescriber and psychiatrist coordinating first.
what's the difference between pharmaceutical-grade and aquarium-grade methylene blue, and does it affect outcomes?
This distinction is not cosmetic. It's the difference between a controlled pharmaceutical product and an industrial chemical sold for fish tanks. USP (United States Pharmacopeia) grade methylene blue is manufactured and tested to pharmaceutical purity standards, with controlled limits on heavy metals and other contaminants, and it's what's used in FDA-approved injectable products [1]. Aquarium or industrial-grade methylene blue has no such purity guarantee. It can contain heavy metals, solvents, or other contaminants left over from manufacturing processes never designed for ingestion, and there is no regulatory body verifying what's actually in the bottle. Any "success rate" discussion is meaningless if the product itself is unverified. Buying methylene blue is really a sourcing decision before it's a dosing decision. This is exactly why Methylene Blue Bio exists as a provider-reviewed resource: it points readers toward pharmaceutical-grade product routes reviewed by a prescriber and fulfilled by a licensed compounding pharmacy, rather than industrial-grade product with no chain of custody.
who should not take methylene blue, regardless of the claimed success rate?
Two groups face real, well-documented risk, separate from whatever benefit is being claimed. First, people with G6PD deficiency, an inherited enzyme deficiency affecting red blood cells. In G6PD-deficient patients, methylene blue can trigger hemolytic anemia (destruction of red blood cells) instead of helping, and it's specifically contraindicated in this population according to FDA prescribing information [1]. G6PD deficiency is more common in people of African, Mediterranean, and Southeast Asian descent, and many people don't know their status unless tested. Second, anyone taking SSRIs, SNRIs, MAOIs, tricyclic antidepressants, or other serotonergic drugs, because of the serotonin syndrome risk described above [7]. Pregnant women, people with kidney impairment, and those with a history of methemoglobinemia from other causes also need individualized medical review before use, per the same prescribing information [1]. None of this is about a success percentage. It's about whether the drug is safe for a given person before efficacy even becomes relevant.
what dose of methylene blue do the human studies actually use?
| Methemoglobinemia (IV, clinical) | 1-2 mg/kg IV, may repeat | FDA label, Provayblue [1] | |
|---|---|---|---|
| Cognitive/fMRI study (single dose, healthy adults) | ~0.5 mg/kg oral | Rodriguez et al., Radiology 2016 [2] | |
| Bipolar depression add-on trial | 15 mg/day (low dose arm) | Naylor et al., 1986 [8] | |
| Alzheimer's LMTM trial | 8 mg/day to 200 mg/day across arms | Gauthier et al., Lancet Neurology 2021 [4] | The spread is enormous, from single-digit milligrams per day in some trials to multi-hundred-milligram doses in the Alzheimer's trials, and these are not interchangeable. A dose studied for methemoglobinemia rescue in a hospital isn't the same as a low, oral, longevity-forum dose, and neither has been tested against the other head to head. |
Doses vary a lot depending on the use case, and this matters because "methylene blue works" without a dose attached is not a useful claim. | Use case | Typical studied dose | Source |
how strong is the evidence, ranked by use case?
Ranking the evidence honestly changes the picture a lot depending on what you're asking it to do. Strongest evidence: methemoglobinemia treatment. This is FDA-approved, has decades of clinical use, and a real, if not single-number, clinical response rate [1]. Moderate but thin: single-dose cognitive effects in healthy adults. Real peer-reviewed trials, but small samples, short duration, and no replication at scale [2] [3]. Weak and contested: Alzheimer's disease treatment via LMTM. Large Phase 3 trial, but it did not meet its primary endpoint versus its comparator [4]. Historical and unconfirmed: mood/antidepressant effects. Old, small trials with promising signals, never modernized or repeated with today's trial standards [8]. Preclinical only, no human data: mitochondrial optimization, biological anti-aging, longevity. Real mechanism in isolated mitochondria and animal models, zero human trials with aging-relevant endpoints [5] [6]. If you're deciding what to actually expect month to month, methylene blue first month what to expect and methylene blue reviews cover the practical, self-reported side of this, which is a different thing from clinical trial data and should be weighted accordingly.
how should you weigh 'success rate' before trying methylene blue off-label?
Be honest with yourself about which claim you're actually testing. If you want it for methemoglobinemia, that's a settled, approved, monitored medical treatment with real clinical response data [1]. If you want it for focus, mood, mitochondria, or anti-aging, you're participating in an off-label, thinly-studied use, and no legitimate source can hand you a validated success percentage for that, because the trial that would generate one hasn't been run. What I'd actually do: if you're curious about off-label use, start with a real conversation with a prescriber who can check for G6PD deficiency, review your current medications for serotonergic interactions, and confirm the product is USP pharmaceutical-grade, not aquarium-grade. Methylene Blue Bio's provider-reviewed pathway connects readers with that kind of prescriber review and routes any prescription through a licensed compounding pharmacy, which is a meaningfully different risk profile than buying an unverified bottle online. What I wouldn't do: assume a rat study or a single small fMRI trial predicts what will happen in your body, or skip the G6PD and medication check because the forum testimonials sound convincing.
Frequently asked questions
What is the success rate of methylene blue for methemoglobinemia?
There's no single published percentage, but methylene blue is first-line, FDA-approved treatment for drug- or chemical-induced methemoglobinemia, and methemoglobin levels typically begin falling within an hour of an IV dose in most patients [1]. Response can be repeated with additional doses if levels stay elevated after 30 to 60 minutes.
Does methylene blue really improve focus and memory?
A small 2016 trial found a single low dose improved short-term memory retention and brain activity in memory-related regions in healthy adults [2]. That's real but limited data: one small study, one dose, no large-scale replication. It doesn't establish a reliable success rate for everyday focus use.
Is methylene blue FDA-approved for energy or nootropic use?
No. Methylene blue is FDA-approved only for treating methemoglobinemia [1]. Any use for energy, focus, mitochondrial support, or anti-aging is off-label, meaning it's legal for a doctor to prescribe that way but it hasn't been studied or approved by the FDA for those purposes.
Can methylene blue cause serotonin syndrome?
Yes. Methylene blue inhibits monoamine oxidase A and can cause serotonin syndrome when combined with SSRIs, SNRIs, or other serotonergic drugs. The FDA has issued a specific safety communication about this interaction [9]. Anyone on antidepressants should not use methylene blue without medical coordination.
Who should avoid methylene blue entirely?
People with G6PD deficiency should avoid it, since it can trigger hemolytic anemia rather than help, per FDA prescribing information [1]. People on serotonergic medications, pregnant women, and those with kidney impairment also need individualized medical review before considering use.
Does methylene blue help with Alzheimer's disease?
The evidence is contested. A 2021 Phase 3 trial of LMTM (a methylene blue-derived compound) published in The Lancet Neurology did not meet its primary cognitive endpoint versus its comparator arm in mild Alzheimer's patients [4]. It's not a confirmed treatment despite years of research interest.
What's the difference between pharmaceutical-grade and aquarium-grade methylene blue?
Pharmaceutical (USP) grade is manufactured and tested to strict purity standards with controlled contaminant limits, and it's what's used in FDA-approved products [1]. Aquarium or industrial grade has no such guarantee and can contain heavy metals or manufacturing byproducts never meant for human ingestion.
Is there human evidence for methylene blue and mitochondrial function?
The mechanism, methylene blue acting as an alternative electron carrier, is demonstrated in isolated mitochondria and animal studies [5][6]. There's no published human trial measuring mitochondrial function or aging biomarkers in people taking it, so no human success rate exists for this use.
What dose of methylene blue was used in the memory study?
The 2016 Radiology study by Rodriguez et al. used a single oral dose of about 0.5 mg/kg in healthy adults [2]. This is far lower than clinical methemoglobinemia doses (1-2 mg/kg IV) and not directly comparable to doses used in Alzheimer's trials.
Does methylene blue treat depression?
Small, old trials, including a 1986 study by Naylor et al. using 15 mg/day as an add-on, reported mood improvement in bipolar depression [8]. These trials are decades old and haven't been repeated at modern standards, so there's no reliable modern success rate for depression treatment.
How is methylene blue dosed for methemoglobinemia in a hospital?
The standard approach is 1 to 2 mg/kg given intravenously over several minutes, with a repeat dose possible if methemoglobin levels remain elevated after 30 to 60 minutes, per FDA prescribing information for methylene blue injection [1].
Can you buy pharmaceutical-grade methylene blue without a prescription?
Injectable pharmaceutical methylene blue is a prescription drug. Oral USP-grade product for off-label use is generally obtained through a prescriber and a licensed compounding pharmacy, which is the route Methylene Blue Bio's provider-reviewed pathway points readers toward, rather than unverified industrial-grade sellers.
Sources
- FDA, Provayblue (methylene blue injection) prescribing information: FDA-approved indication for methemoglobinemia, dosing (1-2 mg/kg IV), G6PD contraindication
- Rodriguez et al., Radiology 2016: Single low-dose methylene blue improved short-term memory and brain activity in healthy adults
- Rodriguez et al., Radiology 2011: Earlier low-dose methylene blue trial on working memory and mood in healthy volunteers
- Gauthier et al., The Lancet Neurology 2021 (LMTM Phase 3): LMTM did not meet primary cognitive endpoint versus comparator in mild Alzheimer's disease trial
- NCBI Bookshelf / pharmacology review, methylene blue mitochondrial electron transport mechanism: Methylene blue acts as an alternative electron carrier in mitochondrial electron transport
- Rodriguez et al./preclinical review, Neurobiology of Aging: Low-dose methylene blue improved oxidative stress markers and learning task performance in rodent models
- FDA Drug Safety Communication on methylene blue and serotonergic drugs: Methylene blue inhibits MAO-A and can cause serious CNS/serotonergic reactions
- Naylor et al., 1986, low-dose methylene blue in bipolar depression: Small trial of low-dose methylene blue (15 mg/day) as add-on treatment reported mood improvement in bipolar depression